Damora Therapeutics (DMRA) Capital Expenditures Growth (1y) (2022 - 2025)
Damora Therapeutics (DMRA) Capital Expenditures Growth (1y) (2022 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,538.84 Bn | 65,538.56 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 469.46 Bn | 464.67 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.69 Bn | 115.45 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.41 Bn | 61.65 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.84 Bn | 62.84 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 143.40% |
| 10 | Damora Therapeutics | 1.02 Bn | 817.32 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 56.94% |
| Sep 30, 2025 | 152.14% |
| Jun 30, 2025 | -18.18% |
| Mar 31, 2025 | -74.05% |
| Dec 31, 2024 | -50.81% |
| Sep 30, 2024 | 288.71% |
| Jun 30, 2024 | 3,155.56% |
| Mar 31, 2024 | 174.53% |
| Dec 31, 2023 | -1,363.73% |
| Sep 30, 2023 | -144.93% |
| Jun 30, 2023 | 65.38% |
| Mar 31, 2023 | 393.02% |
| Dec 31, 2022 | 410.00% |
| Sep 30, 2022 | 121.63% |
| Jun 30, 2022 | -103.35% |
| Mar 31, 2022 | -33.85% |